A NEW APPROACH FOR THE TREATMENT OF COPD AND LUNG CANCER USING INHALED RETROMETABOLIC HSP90 INHIBITORS
Grant number: 1038895 | Funding period: 2012 - 2014
The inflammatory lung disease Chronic Obstructive Pulmonary Disease (COPD) is a major disease burden in Australia with over 1 million sufferers and being the fourth biggest killer. Lung cancer is one of the most difficult cancers to treat with 5-year survival rates being below 20%. There is a pressing need for new therapies to treat these diseases and this project will develop new drugs designed to inhibit an underlying mechanism present in both diseases, with minimal side-effects.